Mount Desert Island Biological Laboratory
Programs and results
What we aim to solve
Our programs
What are the organization's current programs, how do they measure success, and who do the programs serve?
Regenerative Medicine
The MDI Biological Laboratory is pioneering new approaches in regenerative medicine. We are dedicated to understanding the genetic mechanisms responsible for regeneration and to developing therapies to stimulate our natural ability to repair or replace damaged tissues and organs.
Science Education
The MDI Biological Laboratory provides hands-on scientific education to approximately 300 students annually.
Where we work
This profile needs more info.
If it is your nonprofit, add geographic service areas to create a map on your profile.
Login and updateGoals & Strategy
Learn about the organization's key goals, strategies, capabilities, and progress.
Charting impact
Four powerful questions that require reflection about what really matters - results.
What is the organization aiming to accomplish?
We seek to develop novel therapies to address some of our most pressing chronic illnesses such as heart disease, Alzheimer's, Parkinson's, and the degenerative changes that occur as we age.
What are the organization's key strategies for making this happen?
Our scientists are enlisting a unique approach -- identifying the genetic mechanisms that facilitate the body's natural ability to heal and repair damaged tissues and organs. This approach sets us apart from the majority of those in the regenerative medicine field. But we know that this approach is working. In just a few short years, with minimal investment, we have identified three potential new drugs that show promise for treating damaged cardiac, muscle and nervous tissues.
What are the organization's capabilities for doing this?
The MDI Biological Laboratory has 35,000 sq. ft. of state-of-the-art laboratory facilities, outstanding scientific expertise and visionary leadership. Our scientists and staff are dedicated to fully exploiting the potential of regenerative medicine to revolutionize 21st century medicine.
What have they accomplished so far and what's next?
We are receiving federal peer-reviewed grant and publication success and have achieved our initial research milestones. Much work remains to be done. The drug-development process is arduous, expensive and fraught with risk. But if successful, this work will forever change the landscape of medicine.
Financials
Unlock nonprofit financial insights that will help you make more informed decisions. Try our monthly plan today.
- Analyze a variety of pre-calculated financial metrics
- Access beautifully interactive analysis and comparison tools
- Compare nonprofit financials to similar organizations
Want to see how you can enhance your nonprofit research and unlock more insights?
Learn more
about GuideStar Pro.
Operations
The people, governance practices, and partners that make the organization tick.
Connect with nonprofit leaders
SubscribeBuild relationships with key people who manage and lead nonprofit organizations with GuideStar Pro. Try a low commitment monthly plan today.
- Analyze a variety of pre-calculated financial metrics
- Access beautifully interactive analysis and comparison tools
- Compare nonprofit financials to similar organizations
Want to see how you can enhance your nonprofit research and unlock more insights? Learn More about GuideStar Pro.
Connect with nonprofit leaders
SubscribeBuild relationships with key people who manage and lead nonprofit organizations with GuideStar Pro. Try a low commitment monthly plan today.
- Analyze a variety of pre-calculated financial metrics
- Access beautifully interactive analysis and comparison tools
- Compare nonprofit financials to similar organizations
Want to see how you can enhance your nonprofit research and unlock more insights? Learn More about GuideStar Pro.
Mount Desert Island Biological Laboratory
Board of directorsas of 05/10/2017
Peter Allen
Memorial Sloan Kettering
Term: 2015 - 2018
Dr. Edward Benz
Dana Farber Cancer Institute
Term: 2016 - 2019
Edward J. Benz
Terence Boylan
Spencer Ervin
Phoebe C. Boyer
Alan B. Miller
Kevin Strange
Max J. Brenninkmeyer
James L. Boyer
Yale University School of Medicine
Anne Lehmann
I. Wistar Morris
Penn Trust
Ruth Cserr
Peter Allen
Memorial Sloan Kettering
Lewis Kinter
Clare Stone
Margaret Myers
John Hays
Frank L. Hohmann
Bruce Stanton
Joanne Firstenberg
Douglas Elliman
Alan W. Kornberg
Paul, Weiss, Rifkind, Wharton & Garrison LLP
Ned Cloonan
Ned Cloonan & Associates
Josephine Sollano
Pfizer
Daphne W. Trotter
McDermott Will & Emery LLP
Thomas A. Boyd
Anthology BioDevelopment, LLC